Table 3.

Characteristics of tumors and patients who showed recurrence

Age/Gender	Baseline cTN	nCRT	Post nCRT ycTN	Post LE ypT	TRG	Margin	Completion TME surgery	TTLR (months)	Treatment for local recurrence	TTDR	Site of Distant recurrence
53/M	T3N+	Capecitabine + 50.4 Gy	ycT1N0	2	3	Negative	Required/Refused	49	Local re-excision	10	Liver
74/M	T3N+	Capecitabine + oxaliplatin + 50.4 Gy	ycT2N0	2	2	Positive	Required/Refused	32	LAR + IORT	61	Lung
61/M	T3N+	Capecitabine + 55 Gy	ycT0N0	3	3	Negative	Required/Refused	41	APR	53	Liver, lung
79/F	T2N+	Capecitabine + 50.4 Gy	ycT0N0	0	1	Negative	Not required	44	Refused	None	None
72/F	T3N+	Capecitabine +oxaliplatin +50.4 Gy	ycT2N+	0	1	Negative	Not required	41	CRT	45	Adrenal gland
63/M	T2N+	Capecitabine +55 Gy	ycT1N0	0	1	Negative	Not required	None	None	32	Liver, lung
54/F	T2N+	Capecitabine +oxaliplatin +50.4 Gy	ycT2N0	1	4	Negative	Performed	None	None	33	Lung
54/M	T2N0	Capecitabine +oxaliplatin +50.4 Gy	ycT3N0	0	1	Negative	Not required	None	None	101	Nodal, bone
54/M	T3N+	Capecitabine + 55 Gy	ycT3N0	2	3	Negative	Performed	None	None	9	Liver

APR abdominoperineal resection, cTN clinical tumor-nodal stage, LAR low anterior resection, LAR + IORT low anterior resection and intraoperative radiotherapy, LE local excision, nCRT neoadjuvant chemoradiotherapy, TME total mesorectal excision, TTLR time to local recurrence, TTDR time to distant recurrence, ypT post-neoadjuvant chemoradiotherapy pathological tumor stage